Similar to TNBC, the disease progression in HER2+ BC patients have shown a considerable correlation with the immune response and hence it is hypothesized that ICB-based immunomodulation techniques can be used in a favorable way to manage this aggressive cancer as well (19, 20). This evidence concerns the gene ERBB2 and cancer.